IceCure Medical (NASDAQ:ICCM) Upgraded by Alliance Global Partners to Strong-Buy Rating

Alliance Global Partners upgraded shares of IceCure Medical (NASDAQ:ICCM) to a strong-buy rating in a research report sent to investors on Friday, Zacks.com reports.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $2.50 target price on shares of IceCure Medical in a research report on Thursday, September 12th.

IceCure Medical Trading Up 4.8 %

Shares of ICCM stock opened at $0.85 on Friday. IceCure Medical has a 12-month low of $0.48 and a 12-month high of $1.57. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.97 and a quick ratio of 2.54. The firm has a fifty day moving average of $0.63 and a 200-day moving average of $0.78.

IceCure Medical (NASDAQ:ICCM) last announced its earnings results on Tuesday, August 20th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. The business had revenue of $1.01 million for the quarter, compared to analyst estimates of $0.90 million. IceCure Medical had a negative return on equity of 111.27% and a negative net margin of 410.22%. During the same quarter last year, the firm earned ($0.09) EPS. On average, analysts predict that IceCure Medical will post -0.27 EPS for the current fiscal year.

Institutional Trading of IceCure Medical

A hedge fund recently bought a new stake in IceCure Medical stock. Renaissance Technologies LLC acquired a new position in shares of IceCure Medical Ltd (NASDAQ:ICCM) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 66,400 shares of the company’s stock, valued at approximately $49,000. Renaissance Technologies LLC owned 0.15% of IceCure Medical at the end of the most recent reporting period. 0.62% of the stock is currently owned by hedge funds and other institutional investors.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.